At the news
? BEARISHIMPACT 7/10 424B5 filed Aug 14, 2026 at 08:30 ET
Outlook Therapeutics priced a $55M underwritten public offering of 55.6M shares and 55.6M warrants at $0.99/unit, representing ~30% dilution from current shares outstanding. Net proceeds of ~$51.1M will fund the US commercial launch of LYTENAVA (FDA-approved July 2026) and working capital. The offering follows a Q3 FY2026 net loss of $20.3M and a cash position of only $11.2M as of June 30, 2026, with substantial doubt about going concern even after this raise. The company expects the proceeds to fund operations into Q2 2027, but will require additional capital thereafter.
- Offering of 55,555,556 shares of common stock and warrants to purchase 55,555,556 shares at a combined price of $0.99 per unit
- Net proceeds estimated at approximately $51.1 million (before warrant exercise)
- Pro forma as adjusted net tangible book value per share of $0.24, representing immediate dilution of $0.75 per share to new investors
- Cash and cash equivalents of approximately $11.2 million as of June 30, 2026 (preliminary)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access